The main findings of this study are as follows: (a) among AMI patients, those with cancer were generally older and more often presented with comorbidities than those without cancer; (b) patients with cancer tended to be treated with conservative medical strategies with a weaker P2Y12 inhibitor in dual anti-platelet therapy (DAPT) and less PCI; (c) patients with cancer had a significantly higher incidence of cardiovascular mortality and MACCE; (d) patients with a historical cancer diagnosis within 5 years had a higher risk of cardiovascular ischemic events. Here, P2RY12 is linked to cancer.